A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Positive Metastatic Breast Cancer
Interventions: DRUG: Margetuximab Margetuximab-IV
Sponsor: Zai Lab (Shanghai) Co., Ltd.